News Search Results
Mar 31, 2026, 08:39 ET HYDRINITY RetaXome™ Daily Retinal Hydrator Named NewBeauty Best Retinal Serum Following Landmark Clinical Publication
providers to describe RetaXome as the first true "hydrating retinoid." The publication reinforced the position of HYDRINITY at the intersection of biotechnology and dermatological skincare innovation."This recognition from NewBeauty comes at an especially meaningful time for our brand," said Keith
More news about: HYDRINITY Accelerated Skin Science
Mar 31, 2026, 08:15 ET LabConnect Launches SampleGISTICS® 2.0 to Digitize Clinical Trial Sample Capture
LabConnectLabConnect is a global provider of technology-enabled central laboratory services and functional service provider solutions for pharmaceutical, biotechnology and contract research organizations. The company connects laboratories, logistics, technology and scientific expertise through a decentralized laboratory
More news about: LabConnect
Mar 31, 2026, 08:15 ET LabConnect Launches SampleGISTICS® 2.0 to Digitize Clinical Trial Sample Capture
LabConnectLabConnect is a global provider of technology-enabled central laboratory services and functional service provider solutions for pharmaceutical, biotechnology and contract research organizations. The company connects laboratories, logistics, technology and scientific expertise through a decentralized
More news about: LabConnect
Mar 31, 2026, 08:05 ET Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Calif., March 31, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase 1/2 ARROW study evaluating pralsetinib
More news about: Rigel Pharmaceuticals, Inc.
Mar 31, 2026, 08:00 ET Kalohexis Appoints Tony Mitchell as Chief Financial Officer
NORTHBROOK, Ill., March 31, 2026 /PRNewswire/ -- Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced
More news about: Kalohexis
Mar 31, 2026, 08:00 ET OpenProtein.AI Expands Strategic Partnership with Boehringer Ingelheim to Advance AI-Driven Antibody Discovery
seamlessly into existing workflows," said Tristan Bepler, Ph.D., CEO, OpenProtein.AI. "This expanded partnership validates our vision of providing biotechnology and pharmaceutical companies with production-ready AI infrastructure that learns from their proprietary data and adapts to their specific development
More news about: OpenProtein.AI
Mar 31, 2026, 07:34 ET Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
pathways, which may include an LDT route."About Virax Biolabs Group LimitedVirax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is developing T cell-based
More news about: Virax BioLabs Group Limited
Mar 31, 2026, 07:30 ET Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Mar 31, 2026, 06:45 ET Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Mar 31, 2026, 06:34 ET Diagens Biotechnology Raises US$101 Million in Hong Kong IPO; Shares More Than Double on First Day of Trading
HKEXHANGZHOU, China, March 31, 2026 /PRNewswire/ -- Hangzhou Diagens Biotechnology Co., Ltd. (HKEX: 02526) today began trading on the Main Board of The Stock Exchange of Hong Kong. Shares closed at HK$202.60, up 104.65% from the
More news about: Hangzhou Diagens Biotechnology Co., Ltd.
Mar 31, 2026, 06:30 ET Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jon Congleton, a seasoned
More news about: Immunic, Inc.
Mar 31, 2026, 06:15 ET Epson Announces Authorized Distribution Alliance with Clayton Controls to Deliver Advanced Automation Solutions to the Southwest Region
of experience, Epson Robots delivers robots for precision assembly and material handling applications in the aerospace, appliance, automotive, biotechnology, consumer product, electronics, food processing, medical device, pharmaceutical, plastics, semiconductor, and telecommunication industries. For
More news about: Epson America, Inc.
Mar 31, 2026, 05:01 ET Deakin University advances global agenda for affordable health through RAAH Roundtable
participate in the kick-off roundtable.""We believe that the alliance will make sure that all the advances and development in AI, biotechnology and technology should be put to use for better health for everybody, such that we let go of social inequality in health."Welcoming
More news about: Deakin University
Mar 30, 2026, 15:49 ET ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
[email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
Mar 30, 2026, 14:12 ET Texas Healthcare and Bioscience Institute Releases Strategic Vision to Advance the Texas Life Sciences Ecosystem
healthcare and bioscience industry, today released a comprehensive report outlining a strategic vision for strengthening Texas' life sciences and biotechnology ecosystem. "
More news about: Texas Healthcare and Bioscience Institute
Mar 30, 2026, 14:00 ET WesternU COMP celebrates 100% residency placement for third consecutive year
www.westernu.edu), located in Pomona, Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician
More news about: Western University of Health Sciences
Mar 30, 2026, 13:00 ET uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
(short video)UNIQURE N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 30, 2026, 12:34 ET Skyhawk Therapeutics Announces its Founding Scientific Advisory Board Chairman Receives the American Cancer Society's 2026 Medal of Honor
BOSTON, March 30, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets for a series of challenging diseases, announces that the
More news about: Skyhawk Therapeutics
Mar 30, 2026, 10:38 ET QuantiPath Appoints Industry Veteran Michael E. Strauss to Board of Directors
building a world-class leadership team and advancing innovation in food safety diagnostics.About QuantiPathQuantiPath is a biotechnology company revolutionizing food safety testing through precision genetic diagnostics. Its flagship product, GenoPATHx, is the only rapid test kit that
More news about: QuantiPath
Mar 30, 2026, 10:00 ET Sanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence
date, Sanyou has empowered over 1,200 new drug development projects and established solid partnerships with more than 2,000 pharmaceutical and biotechnology companies worldwide.Over the years, Sanyou has continuously increased R&D investment, optimized innovation framework, assembled top-tier
More news about: Sanyou Bio
Mar 30, 2026, 09:53 ET Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
ensuring its innovative platform technologies reached new heights.In 2025 alone, the Company established multiple collaborations with global biotechnology innovators and multinational pharmaceutical companies, including Windward Bio, AstraZeneca, Otsuka, Pfizer and Bristol Myers Squibb. Among these,
More news about: Harbour BioMed
Mar 30, 2026, 09:35 ET Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy
health, and extend lives through the power of science and technology.About Braveheart BioBraveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science
More news about: Braveheart Bio
Mar 30, 2026, 09:05 ET Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Department
More news about: Anixa Biosciences, Inc.
Mar 30, 2026, 09:05 ET Centivax Closes $37 Million Financing to Accelerate Phase 2 Clinical Development of Universal Flu and Advance Follow-On Portfolio to Clinical Readiness
SOUTH SAN FRANCISCO, Calif., March 30, 2026 /PRNewswire/ -- Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced the closing of a $37
More news about: Centivax, Inc.
Mar 30, 2026, 09:00 ET Delonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104
SHANGHAI and PERTH, Australia, March 30, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced the initiation of first-in-human (FIH) dosing in a Phase 1 clinical
More news about: Delonix Bioworks